Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Miyeon Kim is listed as CEO at Genuone Sciences based in Seoul Incheon Metropolitan Area, Korea, Korea, Republic Of. AeroLeads shows a matched LinkedIn profile for Miyeon Kim.
Miyeon Kim previously worked as CEO at Genuone Sciences and Country General Manager at Alcon. Miyeon Kim holds Master Of Business Administration (Mba), Strategy And Marketing from Yale University - Yale School Of Management.
• Senior healthcare leader with broad enterprise experience in pharmaceutical and medical device industry and a track record of driving results • Leadership experience in portfolio strategy development, P&L management, organization development, execution of customer-facing competencies, and business opportunity evaluation• Demonstrated the ability to critically evaluate rapidly changing market dynamics, develop corresponding strategy recommendations, and translate them into executable action plans, • Proven track record of creating high performing teams that exceed expectations and maintaining high employee engagement• Demonstrated collaborative leadership capabilities by forming partnerships with multiple stakeholders to achieve results• Demonstrated the ability to adapt to multicultural, distinct market environments
Listed skills include Business Strategy, Management, Product Launch, Sales Effectiveness, and 11 others.
A career timeline built from the work history available for this profile.
Seoul, South Korea
Genuone Sciences is South Korea’s top CMO pharmaceutical company, specializing in the full range of services for formulation development, manufacturing and clinical development capabilities. Our optimized solutions provide proven, effective and safe medicines and pharmaceuticals of the highest quality.
Gangnam-gu, Seoul, Korea
Developed growth plans, strategic imperatives and transformation plans; Assessed the dynamics of the external environment including pricing reform policies and identified capability gaps to fulfill while laying down infrastructure and governance to pursue further growth opportunities Identified the growth drivers in innovative pipelines; PanOptix, multi.
Korea
Provided leadership in redefining the cardio metabolic portfolio and the growth strategies of new resource planning to sustain the mature brands while leveraging the customer facing platform to launch a new innovative Heart Failure medicine, Entresto. Drove double-digit growth of diabetic portfolio in a highly competitive market environment
Greater New York City Area
Responsible for general management of 90 + mature and post LOE brands and customer-facing capabilities of Sales, Payer Strategy and Consumer Engagement Team Sustaining market leadership of mature brands. Developing Peri LOE strategy of upcoming LOE assets Deploying innovative cost offset programs for LOE portfolios Successfully addressing surged.
Greater New York City Area
Led US Brands Team. Identified numerous innovative ways to compete in the established U.S. pharmaceutical market Managed the P&L of US Brands Team: Attained exceptional financial performance over two years by rejuvenating mature products and containing erosion of post LOE brands Responsible for executing Lipitor US LOE strategy Led the promotion of.
Jung-gu, Seoul, Korea
Led EP Korea business vision, strategy and transformation planning. Established framework of maximizing the base business while setting up frameworks to realize Gx opportunity in Korea. Drove unprecedented double digit growth of Post LOE brands including Lipitor, Caduet, Neurontin, Zoloft and Xalatan by executing thorough business strategies while focusing.
Jung-gu, Seoul, Korea
Led CV Portfolio Marketing Team to refine the portfolio strategies and growth vision per product. Managed LOE of Norvasc, Lipitor and Caduet; sustained market leadership of Norvasc, defended Lipitor and Caduet market share and grew back by double digit. Formed partnership with Novartis to launch Exforge; successfully launched Exforge, and grew the product.
Korea
Developed organization-wide data analytics capabilities and executed new recruitment and development initiatives of marketing talents. Built integrated operation functions to support Sales and Marketing
Korea
Defined the vision of Lipitor as a critical growth driver of Pfizer Korea and implemented strategic growth road map. Successfully managed the cardiovascular issue of Celebrex triggered by Vioxx recall and put Celebrex back into growth trajectory with 45% during the product management period
Korea
Supported Country Manger to build transformative five-year strategic plan of Pfizer Korea. Led a task force team to develop Pfizer Korean vision and implementation plans
Quick answers generated from the profile data available on this page.
Miyeon Kim is listed as CEO at Genuone Sciences.
Miyeon Kim is based in Seoul Incheon Metropolitan Area, Korea, Korea, Republic Of.
Miyeon Kim has worked for Genuone Sciences, Alcon, Novartis, and Pfizer.
You can use AeroLeads to view verified contact signals for Miyeon Kim, including work email, phone, and LinkedIn data when available.
Miyeon Kim holds Master Of Business Administration (Mba), Strategy And Marketing from Yale University - Yale School Of Management.
Miyeon Kim is listed with skills including Business Strategy, Management, Product Launch, Sales Effectiveness, Biotechnology, Oncology, Pharmaceutical Industry, and Pharmaceutical Sales.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contactsCheck these profiles if this is not the Miyeon Kim you were looking for.
